Skip to main content
Top
Published in: Journal of Assisted Reproduction and Genetics 6/2019

01-06-2019 | Fertility | Fertility Preservation

Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield

Authors: Kaitlyn Wald, Hakan Cakmak, Evelyn Mok-Lin, Marcelle Cedars, Mitchell Rosen, Joseph Letourneau

Published in: Journal of Assisted Reproduction and Genetics | Issue 6/2019

Login to get access

Abstract

Purpose

To evaluate the feasibility of utilizing back-to-back random-start ovarian stimulation to increase oocyte yield for fertility preservation prior to cancer treatment.

Methods

A case series of 15 patients who underwent back-to-back random-start stimulation cycles prior to chemotherapy.

Results

Of the 15 back-to-back random-start stimulation cases, 13 had breast cancer and 2 had other cancers. The average age was 38 years (range 30–43) and average AFC was 8 (range 3–14). Fourteen of the 15 women (93%) who underwent two ovarian stimulation cycles completed both of them. The average time to complete back-to-back random-start ovarian stimulation was 33 days (range 13–43 days). The average time between the first cycle completion and the second cycle start in our back-to-back random-start stimulations was 9 days (range 0–14 days). Two of the women underwent back-to-back random-start ovarian stimulation prior to starting neoadjuvant chemotherapy for breast cancer. Eleven of our 15 women at least doubled their oocyte or embryo yield relative to their first cycle. Only 1 of the 15 second cycles was canceled. The mature oocyte rate, fertilization rate, and embryo yield were similar among the first and second cycles.

Conclusions

Back-to-back random-start ovarian stimulation may be an effective way to maximize fertility preservation, even in time-limited settings.
Literature
1.
go back to reference Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.CrossRefPubMed Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.CrossRefPubMed
2.
go back to reference Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121(10):1532–9.CrossRefPubMed Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121(10):1532–9.CrossRefPubMed
3.
go back to reference Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–764 e8.CrossRefPubMed Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–764 e8.CrossRefPubMed
4.
go back to reference Druckenmiller S, Goldman KN, Labella PA, Fino ME, Bazzocchi A, Noyes N. Successful oocyte cryopreservation in reproductive-aged cancer survivors. Obstet Gynecol. 2016;127(3):474–80.CrossRefPubMed Druckenmiller S, Goldman KN, Labella PA, Fino ME, Bazzocchi A, Noyes N. Successful oocyte cryopreservation in reproductive-aged cancer survivors. Obstet Gynecol. 2016;127(3):474–80.CrossRefPubMed
5.
go back to reference Goldman RH, Racowsky C, Farland LV, Munné S, Ribustello L, Fox JH. Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients. Hum Reprod. 2017;32(4):853–9.CrossRefPubMed Goldman RH, Racowsky C, Farland LV, Munné S, Ribustello L, Fox JH. Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients. Hum Reprod. 2017;32(4):853–9.CrossRefPubMed
6.
go back to reference Rebar RW. Social and ethical implications of fertility preservation. Fertil Steril. 2016;105(6):1449–51.CrossRefPubMed Rebar RW. Social and ethical implications of fertility preservation. Fertil Steril. 2016;105(6):1449–51.CrossRefPubMed
7.
go back to reference Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.CrossRefPubMed Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53.CrossRefPubMed
8.
go back to reference Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.CrossRefPubMed Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.CrossRefPubMed
9.
go back to reference Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod BioMed Online. 2014;29(6):684–91.CrossRefPubMed Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod BioMed Online. 2014;29(6):684–91.CrossRefPubMed
10.
go back to reference Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105(6):1488–1495 e1.CrossRefPubMed Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016;105(6):1488–1495 e1.CrossRefPubMed
11.
go back to reference Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100(6):1681–5 e1.CrossRefPubMedPubMedCentral Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100(6):1681–5 e1.CrossRefPubMedPubMedCentral
12.
go back to reference Graham PJ, Brar MS, Foster T, McCall M, Bouchard-Fortier A, Temple W, et al. Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. Ann Surg Oncol. 2015;22(10):3376–82.CrossRefPubMed Graham PJ, Brar MS, Foster T, McCall M, Bouchard-Fortier A, Temple W, et al. Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. Ann Surg Oncol. 2015;22(10):3376–82.CrossRefPubMed
13.
go back to reference Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017;32(10):2123–9.CrossRefPubMed Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017;32(10):2123–9.CrossRefPubMed
14.
go back to reference diZerega GS, Hodgen GD. Folliculogenesis in the primate ovarian cycle. Endocr Rev. 1981;2(1):27–49.CrossRefPubMed diZerega GS, Hodgen GD. Folliculogenesis in the primate ovarian cycle. Endocr Rev. 1981;2(1):27–49.CrossRefPubMed
15.
go back to reference diZerega GS, Hodgen GD. The interovarian progesterone gradient: a spatial and temporal regulator of folliculogenesis in the primate ovarian cycle. J Clin Endocrinol Metab. 1982;54(3):495–9.CrossRefPubMed diZerega GS, Hodgen GD. The interovarian progesterone gradient: a spatial and temporal regulator of folliculogenesis in the primate ovarian cycle. J Clin Endocrinol Metab. 1982;54(3):495–9.CrossRefPubMed
16.
go back to reference Lambertini, M., et al., Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med, 2016. 14: p. 1. Lambertini, M., et al., Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med, 2016. 14: p. 1.
18.
go back to reference Abbara A, Clarke SA, Dhillo WS. Novel concepts for inducing final oocyte maturation in in vitro fertilization treatment. Endocr Rev. 2018;39(5):593–628.CrossRefPubMedPubMedCentral Abbara A, Clarke SA, Dhillo WS. Novel concepts for inducing final oocyte maturation in in vitro fertilization treatment. Endocr Rev. 2018;39(5):593–628.CrossRefPubMedPubMedCentral
19.
go back to reference Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Mullerian hormone. Reprod BioMed Online. 2015;31(4):486–96.CrossRefPubMed Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Mullerian hormone. Reprod BioMed Online. 2015;31(4):486–96.CrossRefPubMed
20.
go back to reference Kotanidis L, Nikolettos K, Petousis S, Asimakopoulos B, Chatzimitrou E, Kolios G, et al. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. J Endocrinol Investig. 2016;39(12):1459–64.CrossRef Kotanidis L, Nikolettos K, Petousis S, Asimakopoulos B, Chatzimitrou E, Kolios G, et al. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. J Endocrinol Investig. 2016;39(12):1459–64.CrossRef
21.
go back to reference Moon KY, Kim H, Lee JY, Lee JR, Jee BC, Suh CS, et al. Nomogram to predict the number of oocytes retrieved in controlled ovarian stimulation. Clin Exp Reprod Med. 2016;43(2):112–8.CrossRefPubMedPubMedCentral Moon KY, Kim H, Lee JY, Lee JR, Jee BC, Suh CS, et al. Nomogram to predict the number of oocytes retrieved in controlled ovarian stimulation. Clin Exp Reprod Med. 2016;43(2):112–8.CrossRefPubMedPubMedCentral
Metadata
Title
Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield
Authors
Kaitlyn Wald
Hakan Cakmak
Evelyn Mok-Lin
Marcelle Cedars
Mitchell Rosen
Joseph Letourneau
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 6/2019
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-019-01462-5

Other articles of this Issue 6/2019

Journal of Assisted Reproduction and Genetics 6/2019 Go to the issue